Skip to main content
Clinical Trials/NCT03695822
NCT03695822
Withdrawn
Phase 4

Far Eastern Memorial Hospital

Far Eastern Memorial Hospital1 site in 1 countryDecember 24, 2018

Overview

Phase
Phase 4
Intervention
Mirabegron 25mg
Conditions
Overactive Bladder Syndrome
Sponsor
Far Eastern Memorial Hospital
Locations
1
Primary Endpoint
Brief symptom rating scale
Status
Withdrawn
Last Updated
7 years ago

Overview

Brief Summary

We will get the impact of mirabegron on psychological distress, urethra and bladder blood flow and c reactive protein.

Detailed Description

Background/Purpose: Pharmacologic treatments for female overactive bladder syndrome (OAB) include antimuscarinics and beta-agonist. Similar efficacy has been reported between antimuscarinics and beta-agonist. Antimuscarinics has been found to be beneficial for patients with psychological distress. However, the impact of mirabegron on psychological distress in female OAB remains unknown. In addition, some animal studies found that beta-3 agonist can improve arterial blood flow, bladder ischemia and might improve bladder function; however, there is still lack of human study. Besides, c reactive protein was found to be elevated in female OAB. Nonetheless there is no study mentioning about the impact of mirabegron on c reactive protein. Thus, the aim of this study is to elucidate the impact of mirabegron on psychological distress, bladder blood flow and c reactive protein.

Registry
clinicaltrials.gov
Start Date
December 24, 2018
End Date
January 31, 2019
Last Updated
7 years ago
Study Type
Interventional
Study Design
Single Group
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Sheng-Mou Hsiao

Chief, Department of Obstetrics & Gynecology

Far Eastern Memorial Hospital

Eligibility Criteria

Inclusion Criteria

  • All OAB female patients
  • \>20 years

Exclusion Criteria

  • Allergy to mirabegron, urinary tract infections

Arms & Interventions

Mirabegron

OAB female patients who will receive beta-3 agonist (mirabegron 2 mg) treatment

Intervention: Mirabegron 25mg

Outcomes

Primary Outcomes

Brief symptom rating scale

Time Frame: 12 weeks

The Brief symptom rating scale (BSRS) includes the following dimensions of psychopathology: somatic symptoms, obsessive-compulsive symptoms, interpersonal sensitivity, depressive symptoms, anxiety symptoms, hostility, phobic-anxiety, and paranoid tendency. Additional symptoms include vegetative and other clinical indicators. The BSRS is composed of 30 items rated on the basis of degree of distress caused by that item over the past week. Each dimension is assessed by several questions with a 5-point Likert scale (0-4 points). The severity of a psychopathologic factor is expressed with an index calculated from the sum of scores divided by the number of questions in that specific dimension. The General Symptom Index (GSI), a mean score of all BSRS items, represents the global severity of psychological distress (PD), and a higher GSI indicates more severe PD. The BSRS has been reported to be a reliable and valid psychiatric self-rating scale for use in psychosomatic research.

Secondary Outcomes

  • Bladder wall blood flow(12 hours)

Study Sites (1)

Loading locations...

Similar Trials